2024 World Conference on Lung Cancer (WCLC) - ePosters-EP.06E.03 Body Composition and Inflammation Index-Based Nomograms to Assess the Outcomes of Patients with NSCLC Receiving Chemoimmunotherapy

EP.06E.03 Body Composition and Inflammation Index-Based Nomograms to Assess the Outcomes of Patients with NSCLC Receiving Chemoimmunotherapy

Back to course

Pdf Summary

The study explored the effects of body composition and inflammation indices on the prognosis of non-small cell lung cancer (NSCLC) patients receiving chemoimmunotherapy. It highlighted that the sarcobesity index, a combination of visceral adiposity and reduced skeletal muscle mass, is a more significant risk factor for survival than sarcopenia alone. Comprehensive assessments were conducted including visceral adipose index (VAI), skeletal muscle index (SMD), and systemic immune-inflammation index (SII), among others.<br /><br />Through LASSO Cox regression, the study identified SII, VAI, and SMD as significant predictors for progression-free survival (PFS) and overall survival (OS). Sarcobesity was associated with worse OS, contrasting with outcomes stratified merely by sarcopenia. High SII, high VAI, and low SMD were linked to the worst PFS and OS, indicating poor prognostic outcomes.<br /><br />Nomograms were developed using these indices, with concordance indices (C-index) of 0.668 for PFS and 0.753 for OS, suggesting moderate predictive accuracy. Calibration plots confirmed strong agreement between predicted and actual survival outcomes, while decision curve analysis (DCA) underscored the model's substantial utility. Patients with sarcobesity had a significantly reduced median OS of approximately 20.233 months compared to 36.833 months in non-sarcobesity patients, underscoring the detrimental impact of excess visceral fat and low muscle mass.<br /><br />The study advocates for future research focusing on strategies to manage inflammation, visceral fat, and muscle loss to potentially enhance treatment outcomes for advanced NSCLC patients. Thus, the study underscores the critical role of inflammation and body composition in prognosis and suggests these elements as targets for improving therapeutic outcomes in NSCLC care.

Asset Subtitle

Qiyu Fang

Meta Tag

Speaker Qiyu Fang

Topic Pathology and Biomarkers

Keywords

non-small cell lung cancer

chemoimmunotherapy

sarcobesity index

visceral adiposity

skeletal muscle mass

systemic immune-inflammation index

LASSO Cox regression

progression-free survival

overall survival

nomograms